-
公开(公告)号：US20240033302A1
公开(公告)日：2024-02-01
申请号：US18235157
申请日：2023-08-17
发明人： Circe Mesa Pardillo , Liliana Oliver Rios , Rydell Alvarez Arzola , Vladimir Pena Sanchez , Luis Enrique Fernández Molina , Anet Valdés Zayas , Maura Lisett Rábade Chediak , Lena Aguiar Garcia , Lourdes Hernández de La Rosa , Audry Fernández Gómez , Leslie Pérez Ruiz , Camilo Rodriguez Rodriguez , Elias Antonio Gracia Medina , Maria Caridad Rubio Hernández , Orlando Valdés Guerrero , Idelmis Curbelo Haredia
摘要： The present invention describes a pharmaceutical composition whose active ingredient includes conjugates of membrane vesicles of Neisseria meningitidis and the GM3 ganglioside in a conjugation ratio in excess of proteins, has particular characteristics of size, surface charge and a morphology associated with nano-particulate systems that give it advantageous properties as an immunomodulator, because it induces a convenient and significant reduction of myeloid-derived suppressor cells that has an impact on the response of T lymphocytes and on the survival of patients with tumors. The invention further discloses the use of the pharmaceutical composition disclosed in the treatment of cancer, particularly those cancers where the myeloid-derived suppressor cells (MDSCs) are high; as well as a method of treatment with said composition in cancer patients and a method to select those who will receive said treatment.
-
公开(公告)号：US09701730B2
公开(公告)日：2017-07-11
申请号：US14440627
申请日：2013-10-30
发明人： Ángel de Jesús Corria Osorio , Kalet León Monzón , Tania Carmenate Portilla , Amaury Pupo Meriño , Saumel Pérez Rodríguez
IPC分类号： C07K14/495 , A61K39/39 , A61K47/48 , A61K38/18
CPC分类号： C07K14/495 , A61K38/1841 , A61K39/39 , A61K47/60 , A61K47/6811
摘要： The present invention relates to the field of Biotechnology and more particularly to the mutated polypeptides of TGFβ molecule whose primary sequence has a high homology with the sequence of human TGFβ. These muteins lose their ability to interact with ALK5 but maintain their ability to interact with other receptors that are part of the receptor complex (TβRII and TβRIII). They have the property of antagonizing the signaling of all natural variants of TGFβ ligands, dependent of ALK5 recruitment in the receptor complex, and have significant immunomodulatory effects. The present invention relates to pharmaceutical compositions comprising as active principle the polypeptides or fusion proteins disclosed and their use thereof given their modulating effect on the immune system in diseases such as cancer, diseases accompanied by fibrosis and chronic infectious diseases.
-
公开(公告)号：US20150284441A1
公开(公告)日：2015-10-08
申请号：US14440627
申请日：2013-10-30
发明人： Ángel de Jesús Corria Osorio , Kalet León Monzón , Tania Carmenate Portilla , Amaury Pupo Meriño , Saumel Pérez Rodríguez
IPC分类号： C07K14/495 , A61K39/39 , A61K47/48 , A61K38/18
CPC分类号： C07K14/495 , A61K38/1841 , A61K39/39 , A61K47/60 , A61K47/6811
摘要： The present invention relates to the field of Biotechnology and more particularly to the mutated polypeptides of TGFβ molecule whose primary sequence has a high homology with the sequence of human TGFβ. These muteins lose their ability to interact with ALK5 but maintain their ability to interact with other receptors that are part of the receptor complex (TβRII and TβRIII). They have the property of antagonizing the signaling of all natural variants of TGFβ ligands, dependent of ALK5 recruitment in the receptor complex, and have significant immunomodulatory effects. The present invention relates to pharmaceutical compositions comprising as active principle the polypeptides or fusion proteins disclosed and their use thereof given their modulating effect on the immune system in diseases such as cancer, diseases accompanied by fibrosis and chronic infectious diseases.
摘要翻译： 本发明涉及生物技术领域，更具体地涉及TGF和bgr的突变多肽; 其一级序列与人TGF-bgr的序列具有高同源性; 这些突变体失去与ALK5相互作用的能力，但是保持与作为受体复合物（T＆Bgr; RII和T＆bgr; RIII）一部分的其他受体相互作用的能力。 它们具有拮抗TGFβb的所有天然变体的信号传导的性质; 配体，依赖于受体复合物中ALK5的募集，并具有显着的免疫调节作用。 本发明涉及药物组合物，其包含公开的多肽或融合蛋白的活性成分及其用途，其给予其对疾病如癌症，伴有纤维化和慢性感染性疾病的疾病对免疫系统的调节作用。
-
公开(公告)号：US20240299518A1
公开(公告)日：2024-09-12
申请号：US18663847
申请日：2024-05-14
发明人： BELINDA SÁNCHEZ RAMÍREZ , GRETCHEN BÁEZ BERGADO , NARJARA GONZÁLEZ SUÁREZ , MABEL CRUZ RODRÍGUEZ , DIANA ROSA HERNÁNDEZ FERNÁNDEZ , LISSET CHAO GARCÍA
CPC分类号： A61K39/001106 , A61K39/001104 , A61P35/00 , A61K2039/55555 , A61K2039/585 , A61K2039/70 , A61K2039/82 , A61K2039/852
摘要： The present invention relates to the branch of Biotechnology and Medicine, particularly to a method for the selection and treatment of patients with carcinomas of epithelial origin that co-express the HER1 and HER2 receptors without increased expression of these receptors or with the presence of RAS activating mutations. In particular, this method is based on the application of bivalent vaccine compositions which have as active principle the extracellular domains of the HER1 and HER2 receptors or portions thereof and as an adjuvant the very small proteoliposomes derived from the outer membrane proteins of Neisseria meningitidis and the GM3 ganglioside. This method is useful for the treatment of patients whose expression levels of HER1 and HER2 do not allow the monoclonal antibodies against HER1 and/or HER2 to have a therapeutic effect.
-
公开(公告)号：US12019073B2
公开(公告)日：2024-06-25
申请号：US16494102
申请日：2018-03-08
发明人： Belinda Sánchez Ramírez , Gretchen Báez Bergado , Narjara González Suárez , Mabel Cruz Rodríguez , Diana Rosa Hernández Fernández , Lisset Chao García
IPC分类号： G01N33/574 , A61K39/00 , A61P35/00
CPC分类号： G01N33/57407 , A61K39/001106 , A61P35/00 , A61K2039/545 , A61K2039/55555 , A61K2039/70
摘要： The present invention relates to the branch of Biotechnology and Medicine, particularly to a method for the selection and treatment of patients with carcinomas of epithelial origin that co-express the HER1 and HER2 receptors without increased expression of these receptors or with the presence of RAS activating mutations. In particular, this method is based on the application of bivalent vaccine compositions which have as active principle the extracellular domains of the HER1 and HER2 receptors or portions thereof and as an adjuvant the very small proteoliposomes derived from the outer membrane proteins of Neisseria meningitidis and the GM3 ganglioside. This method is useful for the treatment of patients whose expression levels of HER1 and HER2 do not allow the monoclonal antibodies against HER1 and/or HER2 to have a therapeutic effect.
-
公开(公告)号：US20190275132A1
公开(公告)日：2019-09-12
申请号：US16398334
申请日：2019-04-30
发明人： Belinda Sanchez Ramirez , Arianna YGlesias Rivera , Amelia Gutierrez Perez , Narjara Gonzalez Suarez
IPC分类号： A61K39/00
摘要： The invention describes vaccine compositions combined in the same proportion with the extracellular domains of growth factor receptors Her1 and Her2 or fragments thereof and furthermore very small size proteoliposomes derived from proteins of the outer membrane of Neisseria meningitidis and GM3 ganglioside (VSSP-GM3), administered subcutaneously. The disclosed compositions, which induce the production of antibodies are used for the treatment of malignancies and offer advantages because they completely remove the tumor mass thus preventing tumor regression due to the emergence of resistant variants.
-
公开(公告)号：US10000573B2
公开(公告)日：2018-06-19
申请号：US15609625
申请日：2017-05-31
发明人： Ramakrishnan Melarkode , Pradip Nair , Sundaraj David Rajkumar , Kedarnath Nanjund Sastry , Monalisa Chatterji , Laxmi Adhikary , Hema Balasubramanian , Jose Enrique Montero Casimiro , Josefa Lombardero Valladares , Rolando Perez Rodriguez
IPC分类号： A61K39/395 , C07K16/28 , A61K45/06 , A61K39/00
CPC分类号： C07K16/2896 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/2809 , C07K2317/24 , C07K2317/732 , C07K2317/76
摘要： The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.
-
8.发明申请公开(公告)号：US20180016353A1
公开(公告)日：2018-01-18
申请号：US15549087
申请日：2016-03-11
发明人： MeyLen CHEA , Julio PALACIOS , Miguel ARIAS , Loany CALVO , Tamara GONZÁLEZ , Rolando PÉREZ , Zhi BAI , Yuemao LIU , Kaiheng XIAO , Xiao CHEN , Zhenhua HE , Yangliu CAI , Zhenhua YANG , Xianhong BAI
摘要： Provided is a method for obtaining high-yield, stable expression cell clones from myeloma cell lines in a protein-free culture medium. The method is used for industrial production of a recombinant antibody, and includes three stage: (1) adapting to a protein-free culture medium, statically culturing cells at a low density, and gradually reducing a fat-rich supplement to a chemical culture medium; (2) adapting to a protein-free culture medium; culturing cells at a high density, and using a perfusion fermentation system in a laboratory scale; and (3) screening high-yield, stable expression cell clones from the cells after fermentation ends. The cell clone may be used to produce a humanized anti-NeuGcGM3 14F7 recombinant antibody.
-
9.发明申请CONJUGATE COMPRISING ERYTHROPOIETIN AND A BRANCHED POLYMER STRUCTURE 审中-公开包含ERYTHROPOIETIN和分支聚合物结构的结合公开(公告)号：US20160317674A1
公开(公告)日：2016-11-03
申请号：US15108862
申请日：2015-01-08
发明人： Rolando PÁEZ MEIRELES , Daniel Enrique AMARO GONZÁLEZ , Fidel Raúl CASTRO ODIO , Yenisel HERNÁNDEZ VALDES , Gladys Amalia RUIZ ESTRADA
CPC分类号： A61K47/60 , A61K38/1816
摘要： The present invention discloses a conjugate comprising erythropoietin (EPO) and an asymmetric branched polymeric structure comprising two branches of monomethoxypolyethylene glycol (mPEG), where the molecular mass of one of these mPEG branches is between 10 kDa and 14 kDa, and the molecular mass of the other branch of mPEG is between 17 kDa and 23 kDa, as well as the pharmaceutical compositions containing it. The invention also provides a method for the preparation of pegylated EPO, wherein said protein is conjugated to an asymmetric branched polymeric structure with two branches of mPEG having the above described molecular masses.
摘要翻译： 本发明公开了一种包含促红细胞生成素（EPO）和包含两个分支的单甲氧基聚乙二醇（mPEG）的不对称支链聚合物结构的缀合物，其中这些mPEG分支之一的分子量在10kDa至14kDa之间，分子质量 mPEG的另一个分支是17kDa至23kDa，以及含有它的药物组合物。 本发明还提供了一种制备聚乙二醇化EPO的方法，其中所述蛋白质与具有上述分子量的两个具有mPEG分枝的不对称支化聚合物结构缀合。
-
10.发明申请PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF TUMORS EXPRESSING EGFR AND GM3 N-GLYCOLYL GANGLIOSIDE (NeuGcGM3) 有权用于治疗表达EGFR和GM3 N-甘氨酰甘油的肿瘤的药物组合物（NeuGcGM3）公开(公告)号：US20140363494A1
公开(公告)日：2014-12-11
申请号：US14369435
申请日：2012-12-04
发明人： Adys González Palomo , Adriana Carr Perez , Kalet León Monzón , Rancés Blanco Santana , María del Carmen Barroso Alvarez , Amparo Emilia Macías Abraham , José Enrique Montero Casimiro
IPC分类号： C07K16/28 , A61K39/00 , A61K39/395 , C07K16/30
CPC分类号： C07K16/2863 , A61K39/0011 , A61K39/3955 , A61K39/39558 , A61K2039/505 , A61K2039/507 , A61K2039/545 , C07K16/3084 , C07K16/4266 , C07K2317/24 , C07K2317/76 , A61K2300/00
摘要： The present invention relates to pharmaceutical compositions for the treatment of malignant tumors. Particularly those tumors that express EGFR and GM3 N-glycolyl ganglioside targets to enhance the therapeutic effect produced by separated therapies against these targets. The pharmaceutical compositions of the invention include antibodies and/or vaccines against each of the targets. Additionally the present invention relates to methods for applying the compositions of the invention.
摘要翻译： 本发明涉及用于治疗恶性肿瘤的药物组合物。 特别是那些表达EGFR和GM3 N-糖基神经节苷脂的肿瘤靶向，以增强分离疗法对这些靶标产生的治疗效果。 本发明的药物组合物包括抗各种靶标的抗体和/或疫苗。 另外本发明涉及应用本发明组合物的方法。
-
-
-
-
-
-
-
-
-
搜索结果
31 条记录 (耗时 0.02 秒)
